ClinicalTrials.gg
RecruitingNCT07255469METAFRICUpdated Dec 1, 2025

Metabolic Fluid Responsiveness in Children

An observational study in Circulatory Failure / Shock State and Fluid Therapy, sponsored by University Hospital, Bordeaux. Recruiting at 8 sites in France. Open to participants aged 0 Days to 15 Years. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by University Hospital, Bordeaux · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
110
Ages
0 Days to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 107 studies in Shock with a site in France — 24 open to participants now, 27 under way, 1 of them phase 3. Shock · France.

Planned enrollment
26th of 61
110 · median 100
Started
2025
with 4 others
Observational
61 of 107
17 open now
Primary completion
2027-03
later than 10 of 26 live
Registered
95th of 107
by date
Lead sponsor
6 of 107
University Hospital, Bordeaux

Among the 107 studies in Shock with a site in France, this one is the 26th largest by planned enrollment of the 61 observational ones that give a count, is one of 5 that started in 2025, is one of 61 observational ones, reaches primary completion later than 10 of the 26 other live ones, and was the 95th registered.

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

Browse Shock studies →

Open to participants now

24 of the 107 studies in Shock with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.

This study: 0 Days to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Shock with a site in France, or all of them as a file.
02

Study summary

The investigators aim to validate markers of metabolic fluid-responsiveness in children with acute circulatory failure following cardiac surgery. This would allow physicians to identify which patient could benefit the most from fluid expansion, thus avoiding useless and potentially dangerous fluid expansions that could lead to fluid overload. To this end, The investigators will evaluate the diagnostic accuracy of the ratio of central venous to arterial carbon dioxide tension (Pv-aCO2) to arteriovenous oxygen content (CavO2), a simple biological marker of anaerobic metabolism, for the diagnosis of metabolic fluid responsiveness defined as a significant increase in oxygen consumption (VO2) after fluid expansion.

Read the detailed description

Acute circulatory failure, defined as a mismatch between oxygen delivery and consumption, is a frequent but serious condition in children after cardiac surgery. Fluid expansion is the cornerstone of acute circulatory failure treatment, but several studies have highlighted the adverse effects of excessive fluid expansion. Therefore, it is crucial to assess the individual benefit-risk ratio before each fluid expansion. Currently, finding fluid responsiveness tests is a major issue in intensive care. Usually, fluid responsiveness is defined as a significant improvement in stroke volume after fluid expansion. However, this is an intermediate objective, as the ultimate goal of the treatment is to restore an adequate balance between oxygen delivery and consumption. In adults, a significant proportion of hemodynamically successful volume expansions (i.e. resulting in a significant increase in stroke volume) are in fact metabolically ineffective, as they do not result in a significant increase in VO2. Certain biological parameters indicating anaerobiosis, such as the Pv-aCO2/CavO2 ratio, could be predictive of metabolic fluid responsiveness (e.g. a significant increase in VO2) in these patients. This has never been investigated in children.

The main objective of this study will be to evaluate the diagnostic accuracy of the Pv-aCO2/DAVO2 ratio at baseline for the diagnosis of metabolic fluid responsiveness, in children hospitalized in intensive care after cardiac surgery, for whom a fluid expansion was prescribed by the physician in charge.

The investigators will conduct a non-interventional, multicentric diagnostic accuracy study in French pediatric intensive care units. VO2 will be measured at baseline (e.g. before fluid expansion) and within 1h after fluid expansion by the combination of echocardiographic assessment and both arterial and venous blood gas. Blood gas are routinely measured, in patients already implanted with arterial and central line, to help manage acute circulatory failure. Echocardiography assessment, which is noninvasive and nonradiative, is also a common practice in this situation. Additional simple demographic, hemodynamic and clinical data will be collected at baseline and within 1 hour after fluid expansion, if monitored. No supplemental blood test or invasive parameter will be collected. These data will be collected from standard monitoring and/or from the patient's medical record.

The primary outcome is the diagnostic accuracy (measured by the area under the receiver operating characteristics curve) of the index test (Pv-aCO2/DAVO2 ratio at baseline) for the diagnostic of metabolic fluid responsiveness, defined as a 15% increase in VO2 after fluid expansion compared to baseline (gold standard test).

  • VO2 (ml/min/m2) will be measured as follow, at baseline and within 1h after fluid expansion: VO2=(10.CO.DAVO2)/(Body Surface Area)
  • DAVO2: difference between arterial and venous oxygen content (measured by blood gas analysis)
  • CO: cardiac output, measured by transthoracic echocardiography as the product of heart rate, left ventricular outflow tract surface (from a parasternal long axis view) and left ventricular outflow tract velocity-time integral (from an apical 5-chambers view).

The secondary outcomes are:

  • Diagnostic accuracy (AUROC, %) of the following index tests for the diagnosis of metabolic fluid responsiveness: arterial lactate, central venous oxygen saturation, Pv-aCO2.
  • Association between fluid expansions induced tissular oxygen saturation variation and metabolic fluid responsiveness.
  • Association between metabolic fluid responsiveness and hemodynamic profile (4 categories, depending on the increase of mean arterial pressure and/or stroke volume after fluid expansion)
  • Subgroup analysis of the primary outcome: age, type of fluid expansion, circulatory physiology
  • Association between baseline clinical data and metabolic fluid responsiveness Study design: non-interventional study of diagnostic accuracy (non-interventional, prospective, multi center). After a prescription of 10 ml/kg volume expansion by the physician in charge, screening for inclusion and exclusion criteria will be performed by an investigator physician. If the patient is included, volume expansion will be delayed for a few minutes (\<5 min) while VO2 and the index test are measured. Within one hour after volume expansion, VO2 will be measured once again to evaluate the metabolic response to fluid expansion (gold-standard test).

Inclusion criteria: Age between 0 days and 15 years old; Patient hospitalized in an intensive care unit after cardiac surgery; Prescription of a 10ml/kg fluid expansion by the physician in charge; Prescription of arterial and venous blood gas before and after the volume expansion to help manage acute circulatory failure; Patient implanted with a functioning arterial line; Patient implanted with a functioning central venous line in the superior vena cava territory Exclusion criteria: Patient less than 37 weeks' corrected gestational age; Hemodynamic instability making the delay necessary for any test dangerous; Supine position contraindicated or deleterious; Impairment of echocardiographic acoustic window or restless patient making ultrasonography impossible; Opposition to participate expressed by the patient or by a parent or legal guardian Number of subjects: One hundred and ten patients are needed. This was calculated with the Obuchowski method, with an alpha risk of 0.05, a statistical power of 80%, a ratio "responder/non-responder" of 3, a predicted area under the receiver operating characteristics curve of 0.85 (based on previous studies) with a confidence interval greater than 0.75 which is a classic threshold for clinical pertinence.

Statistical analysis: Comparisons between metabolic "responders" and "non-responders" (to fluid expansion) will be performed with Student's t-test or Mann-Whitney test for continuous variables; or with the Chi-2 test or Fisher's exact test for categorical variables.

Metabolic fluid responsiveness represents the gold standard test. Patients will be classified as metabolic fluid responders in case of at least 15% increase in VO2 after fluid expansion, compared to baseline.

Diagnostic accuracy of the index tests will be explored. As multiple cut-offs of theses index tests can be defined, the investigators will report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test. The Youden index will also be calculated. The ROC curves of all index tests will be compared using a DeLong test.

A p value less than 0.05 will be considered statistically significant.

03

Conditions studied

  • Circulatory Failure / Shock State
  • Fluid Therapy

Browse trials for

Keywords

  • Circulatory failure
  • Critical Care
  • Echocardiography
  • Fluid therapy
  • Fluid responsiveness
  • Goal-directed fluid management
  • oxygen consumption
  • pediatrics
  • volume expansion
04

Who can participate

Ages eligible
0 Days to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient hospitalized in an intensive care unit after cardiac surgery with a prescription of a 10ml/kg fluid expansion by the physician in charge

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age less than or equal to 15 years old
  • Hospitalization in a pediatric intensive care unit after cardiac surgery
  • Prescription by the attending physician of a fluid expansion of 10ml/kg
  • Prescription of arterial and venous blood gas before and after the volume expansion to help manage acute circulatory failure
  • Patient implanted with a functioning arterial line
  • Patient implanted with a functioning central venous line in the superior vena cava territory

Exclusion criteria

Exclusion Criteria:

  • Patient less than 37 weeks' corrected gestational age
  • Hemodynamic instability making the delay necessary for any test dangerous
  • Supine position or deleterious
  • Impairment of echocardiographic acoustic window or restless patient making ultrasonography impossible
  • Opposition to participate expressed by the patient or by a parent or legal guardian
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
110 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Area under the ROC curve (AUROC, %) of baseline Pv-aCO2/DAVO2 ratio to diagnose metabolic fluid

    The primary outcome measure of a diagnostic accuracy study is the discriminative ability of an index test (expressed as an area under the ROC curve) to diagnose a condition (defined by a positive gold-standard reference test). In this study: * The index test is the baseline Pv-aCO2/DAVO2 ratio, i.e. the ratio between the veno-arterial carbon dioxide partial pressure gradient (mmHg) and the difference between arterial and venous oxygen content (ml.dl-1). Oxygen content and carbon dioxide partial pressure are measured by arterial and central venous blood gas analysis. * The condition is "metabolic fluid responsiveness" * The gold-standard reference test to diagnose metabolic fluid responsiveness is a VO2 increase of at least 15% between baseline and after volume expansion (i.e. ((VO2 after volume expansion - VO2 at baseline) / VO2 at baseline) \> 15%). VO2 (ml/min/m2) will be measured as follow: VO2=(10.CO.DAVO2)/(Body Surface Area), where CO (ml.min-1) is the cardiac output, measured b

    Time frame: at baseline

Secondary outcomes

  1. AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )

    Baseline arterial lactate (mmol.L-1), from an arterial blood gas analysis

    Time frame: at baseline

  2. AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )

    Baseline central venous oxygen saturation (%), from a central venous blood gas analysis

    Time frame: at baseline

  3. AUROC (%) of the following index test to diagnose metabolic fluid responsiveness (same definition as above )

    Baseline Pv-aCO2 (mmHg), from an arterial and central venous blood gas analysis

    Time frame: at baseline

  4. Subgroup analysis of the primary outcome

    age, type of fluid expansion, circulatory physiology

    Time frame: at baseline

  5. Correlation between metabolic fluid responsiveness and the following

    * Age (0 - 2 years / 2 - 5 years / 5 - 15 years) * Sex * Weight * Number of fluid expansion during the last 24 h * Baseline Heart rate * Baseline arterial pressure * Baseline urine output * Baseline capillary refill time * Baseline mottling * Baseline left atrial pressure, if monitored as usual care * Baseline PELODS2 score * Type of volume expansion (albumin or crystalloid) * % of increase in cerebral near-infrared regional spectrophotometry (NIRS, %) ( baseline / after volume expansion) * % of increase in systemic near-infrared regional spectrophotometry (NIRS, %) ( baseline / after volume expansion) * % of increase in mean perfusion pressure (i.e. difference between mean arterial pressure and central venous pressure) ( baseline / after volume expansion) * % of increase in central venous pressure ( baseline / after volume expansion) * Hemodynamic profile

    Time frame: at baseline

  6. Correlation between metabolic fluid responsiveness and the following

    * Length of mechanical ventilation (days), evaluated 28 days after inclusion * Intensive care unit length of stay (days), evaluated 28 days after inclusion. * Mortality at 28 days after inclusion

    Time frame: at baseline , 28 days

07

Study locations

6 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 120 non-industry observational studies under Shock, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 24 months is close to that.

Counting every sponsor, half of 127 studies reached it within 26 months; a quarter within 12 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Dec 1, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Mar 21, 2027
CompletionEst.
Apr 18, 2027
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07255469
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Mar 21, 2025
Primary completion
Mar 21, 2027 (estimated)
Completion
Apr 18, 2027 (estimated)
Last update
Dec 1, 2025

Study contacts

Julin GOTCHAC, MD
Contact
julien.gotchac@chu-bordeaux.fr
+33 5 24 54 92 19 ext. +33
Julien GOTCHAC, MD
study director · CHU de Bordeaux - Hôpital Cardiologique Haut Lévêque

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion